Key result
RAS and AGEs pathway cross-talk influences diabetic retinopathy progression and offers new therapeutic targets.
Why the study?
The absence of an ideal therapy for diabetic retinopathy is due to incomplete understanding of the biochemical mechanisms and their impact on retinal cells.
What is the role of the renin-angiotensin system and advanced glycation end-products in diabetic retinopathy?
Population
Patients with diabetic retinopathy and pre-clinical models
Comparison
Renin-angiotensin system and advanced glycation end-products pathways
Design
Review
Authors
Loading...
Hypothesis-generating for dual RAS-AGE targeting in diabetic retinopathy; prospective trials needed before any practice consideration.
What is the role of the renin-angiotensin system and advanced glycation end-products in diabetic retinopathy?
Understanding the synergistic interactions between the renin-angiotensin system and advanced glycation end-products may lead to novel therapeutic strategies for diabetic retinopathy.
Miller et al. (2013) conducted a review in Diabetic retinopathy. Renin-angiotensin system (RAS) and advanced glycation end-products (AGEs) was evaluated. The renin-angiotensin system and advanced glycation end-products pathways exhibit cross-talk that influences the progression of diabetic retinopathy, offering potential targets for new treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: